Intellectual Property Protection

The Congress in Uruguay approved the bill presented by the Executive in December 1997. It is deficient and contrary to the interests of the research-based pharmaceutical industry. In the most general terms:

Potential Export/Foreign Sales

The removal of current barriers would mean an increase in sales and exports in the range of US$50 million to US$100 million for PhRMA members.